Global RSV Vaccine Market Size To Exceed USD 2.55 Billion by 2035 | CAGR 5.14%
Category: HealthcareGlobal RSV Vaccine Market Size To Exceed USD 2.55 Billion by 2035
According to a Research Report Published By Spherical Insights & Consulting, The Global RSV Vaccine Market Size is Expected to Grow from USD 1.47 Billion in 2024 to USD 2.55 Billion by 2035, at a CAGR of 5.14% during the Forecast Period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 240 pages with 120 Market data tables and figures & charts from the report on the "Global RSV Vaccine Market Size, Share, and COVID-19 Impact Analysis, By Types of Vaccine (Subunit / Viral-like-Particle (VLP) Vaccines, Live Attenuated Vaccines, and mRNA Vaccines), By Distribution Channel (Pharmacies and Drug Stores, Government / Institutional Suppliers and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/rsv-vaccine-market
The RSV Vaccine Market Size is the global industry focused on developing, producing, and distributing vaccines that target the respiratory syncytial virus (RSV) market. It covers a range of immunization types that are administered by intramuscular injections and other means, including live attenuated, subunit, and mRNA vaccines. RSV vaccines prevent infections and other severe respiratory diseases like pneumonia and bronchitis by strengthening the immune system's capacity to recognize and fight the respiratory syncytial virus. The creation of more practical and efficient RSV vaccines is being driven by advancements in vaccine formulation, adjuvants, and delivery systems, which are improving market opportunities. The development and widespread use of RSV vaccinations, which aim to reduce the incidence, severity, and socioeconomic RSV-related illnesses, are motivated by the substantial disease burden associated with RSV infections. Market expansion is anticipated to be fueled by rising awareness of RSV vaccination, the rising prevalence of RSV illnesses worldwide, and technological advancements in vaccine development. The market for RSV vaccines is driven by several important factors, including rising hospitalization rates from the virus, increased knowledge of its detrimental health effects, especially for young children and the elderly, and ongoing advancements in vaccine technology. However, growth is restricted by high development costs, regulatory barriers, a lack of knowledge, supply chain problems, efficacy challenges, and market competition.
The subunit / viral-like-particle (VLP) vaccines segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the type of vaccine, the RSV vaccine market is divided into subunit / viral-like-particle (VLP) vaccines, live attenuated vaccines, and mRNA vaccines. Among these, the subunit / viral-like-particle (VLP) vaccines segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The subunit/viral-like-particle (VLP) vaccines are named for the fact that, because of their physical similarity to their parent virus, they elicit highly repeated immunogenic responses.
The pharmacies and drug stores segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the distribution channel, the RSV vaccine market is divided into pharmacies and drug stores, government / institutional suppliers, and others. Among these, the pharmacies and drug stores segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Given that the majority of people live close to a pharmacy or drugstore, the main reasons for their existence are their accessibility and convenience.
North America is expected to hold the majority share of the global RSV vaccine market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global RSV vaccine market during the forecast period. The present market dynamics include the use of new vaccine technologies, the expansion of pediatric immunization campaigns, and a concerted effort to lower hospitalizations associated with RSV.
Asia Pacific is anticipated to grow at the fastest pace in the global RSV vaccine market during the forecast period. The Asia-Pacific area is seeing a surge in demand for RSV vaccines due to a combination of government-led initiatives, healthcare infrastructure expansion, and growing awareness.
Europe is predicted to hold a significant share of the RSV vaccine market throughout the estimated period. In the context of the RSV Vaccine Market, Europe stands for the collective efforts of all European nations to combat RSV infections.
Major vendors in the global RSV vaccine market are Pfizer Inc., Moderna Inc., Sanofi, Novavax Inc., AstraZeneca plc, Merck & Co. Inc., GlaxoSmithKline, Beijing Advaccine Biotechnology, GlaxoSmithKline plc (GSK), and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In April 2025, the marketing authorization for Pfizer Inc.'s alternating respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, ABRYSVO®, has been updated by the European Commission (EC) to include the prevention of lower respiratory tract disease (LRTD) caused by RSV in people aged 18 to 59.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the RSV vaccine market based on the below-mentioned segments:
Global RSV Vaccine Market, By Type of Vaccine
- Subunit / Viral-like-Particle (VLP) Vaccines
- Live Attenuated Vaccines
- mRNA Vaccines
Global RSV Vaccine Market, By Distribution Channel
- Pharmacies and Drug Stores
- Government / Institutional Suppliers
- Others
Global RSV Vaccine Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?